A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease
Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, Ronald G. Thomas, Robert A. Rissman, Judy Pa, Vahan Aslanyan, Archana Balasubramanian, Tim West, Maria Maccecchini, Howard H. Feldman
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease'. Together they form a unique fingerprint.